| Symbol | FBIOP |
|---|---|
| Name | FORTRESS BIOTECH, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1111 KANE CONCOURSE,SUITE 301, BAY HARBOR ISLANDS, Florida, 33154, United States |
| Telephone | +1 781 - 652-4500 |
| Fax | — |
| — | |
| Website | https://www.fortressbiotech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001429260 |
| Description | Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors. Additional info from NASDAQ: |
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)
Read moreJourney Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
Read moreFortress Biotech and Subsidiary Urica Therapeutics Announce CrystalysTherapeutics’ $130 Million Series B Financing
Read moreFortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Read moreJin David 🟢 acquired 400.0K shares of Fortress Biotech, Inc. (FBIO) Transaction Date: Jun 22, 2026 | Filing ID: 000003
Read moreJourney Medical Corporation to Participate inA.G.P.’s Annual Virtual Healthcare Conference
Read moreFortress Biotech to Participate in A.G.P.’sAnnual Virtual Healthcare Conference
Read moreFortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
Read moreNew Form SCHEDULE 13G/A - Fortress Biotech, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000919574-26-003180 <b>Size:</b> 9 KB
Read more